Detailed Narrative
Q2 FY26 Financial Performance Overview
Dhanuka Agritech reported a challenging Q2 FY26, with revenue from operations at ₹598.25 crores, marking an 8.56% decline from ₹654.28 crores in Q2 FY25. EBITDA also saw a significant drop of 14.20% to ₹136.73 crores, down from ₹159.58 crores in the prior year. Profit after tax (PAT) decreased by 20.04% to ₹93.97 crores compared to ₹117.52 crores in Q2 FY25, reflecting the impact of various headwinds during the quarter.
Impact of Adverse Weather Conditions
The company's Q2 performance was severely affected by abnormal and uneven rainfall distribution across India. This led to significant crop losses, delayed harvesting, and reduced application of agrochemicals. Regions experienced both excess rainfall causing waterlogging and deficient showers, creating uneven soil moisture conditions, which collectively lowered demand for agrochemical products and contributed to the revenue decline.
Biostimulant Business Update and Regulatory Challenges
Sales of biostimulants were negatively impacted by the sudden implementation of a new regulatory framework by the Government of India, which temporarily halted sales of existing products. This regulatory change resulted in an estimated impact of over ₹20 crores on revenue in Q2 FY26. Management expects biostimulant sales to begin recovering by Q1 FY27 as new product clearances are obtained under the updated framework.
Dahej Plant and New Product Development
Dhanuka Agritech has commenced trial production of its second product, Difenoconazole, at the Dahej plant, with an estimated potential of 200 metric tons for the Indian market. Sales of Bifenthrin Technical from Dahej are progressing as planned. The company aims for the Dahej plant to achieve EBITDA profitability by FY27, despite reporting a nominal EBITDA loss of ₹46 lakhs in Q2 FY26.
Bayer Products Integration and Revised Outlook
The integration of products acquired from Bayer (Melody Duo, Triadimenol) is underway, with India market sales reaching approximately ₹25 crores in H1 FY26. However, delays in international registration transfers have led to a downward revision of the FY26 overall sales guidance for Bayer products to around ₹40 crores, from an initial projection of ₹100 crores. Royalty income from Bayer is expected to increase, with ₹13.5 crores already received in H1.
Rabi Season Outlook and H2 FY26 Projections
The extended monsoon and October rains have caused delays in kharif harvesting and the commencement of rabi sowing, pushing business activity into November and December. Despite this slow start, management anticipates a relatively better H2 FY26 due to favorable soil moisture and water availability. The company projects a 2-3% growth in H2 FY26, aiming for a flattish revenue performance for the full FY26.
Strategic Focus on Backward Integration and Acquisitions
Dhanuka Agritech continues to prioritize backward integration, with plans to begin manufacturing Iprovalicarb in India by FY27. The company also remains open to strategic acquisitions, leveraging its debt-free and strong balance sheet to explore growth opportunities. International collaborations with 10 global agrochemical companies are key to introducing the latest technologies in India.
Sales Returns and Herbicides Segment Performance
Sales returns increased significantly in Q2 FY26, primarily attributed to continuous rains that impacted the herbicides segment. This particularly affected specialty herbicides used in crops like soybean, groundnut, and cotton, as adverse climatic conditions prevented farmers from applying these products. The herbicides category contributed only 9% to the Q2 turnover, highlighting its vulnerability to weather-related disruptions.